The Development of A Novel Blood Biomarker for Detecting AR-V7 and Resistance to Zytiga and Xtandi

At the current AUA Annual Meeting going on in New Orleans, there was a presentation given by Haitao Zhang and colleagues. They described their work developing a novel blood-based assay (test) for detecting androgen receptor (AR) splice variants in men with advanced prostate cancer. Their work relies on the premise that AR-V7 expression underlies resistance [...]

PSA Decline is a Potential Biomarker for Identifying Early Resistance to Zytiga and Xtandi In Men Who are Post Chemotherapy*

Abiraterone Acetate (Zytiga) and enzalutamide (Xtandi) are the newest generation hormonal agents.  They both have demonstrated a survival advantage in men with castrate resistant prostate cancer (CRPC) who have already been treated with docetaxel (chemotherapy). Unfortunately all men who are responsive to both of these drugs eventually become resistant.   Some men are subject to early [...]

Can B7-H3 Expression Serve as a Biomarker of Biochemical Recurrence after Salvage Radiation Therapy for Recurrent Prostate Cancer?

Current knowledge makes it very difficult to predict which men will experience biochemical recurrence (BCR) after salvage radiation therapy (SRT) for recurrent prostate cancer (PCa). We are also lacking in novel targets for adjuvant therapies. At the College of Medicine, Mayo Clinic Florida, Jacksonville, FL., researchers evaluated the association of B7-H3 expression in primary PCa [...]

Stromal Biomarker Appears to Predict Advanced Prostate Cancer

The absence of a stromal protein called caveolin-1 appears to be a marker for advanced prostate cancer and for metastasis, researchers from the Kimmel Cancer Center at Jefferson and Harvard Medical School reported in "Cell Cycle." Caveolin-1 has already been shown to be a good biomarker serving as a prognostic factor for breast cancer. The [...]